DL
Therapeutic Areas
Ipsen Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Ojemda® (tasurgratinib) | Pediatric cancers with NTRK fusions | Regulatory Review |
| IPN60340 (ICT01) | 1st-line unfit Acute Myeloid Leukemia (AML) | Phase 2/3 |
| IQIRVO® (elafibranor) | Primary Biliary Cholangitis (PBC) | Marketed / Late-stage Study |
| Undisclosed Asset | Rare Neurodegenerative Diseases | Pre-clinical |
| Early I-O Pipeline | Various Solid Tumors | Pre-clinical / Phase 1 |